^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK inhibitor

    Related drugs:
    Apply
    Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/11/2011
    Primary completion :
    03/28/2023
    Completion :
    08/02/2025
    BRCA1 • BRCA2 • BRCA • RAD51
    |
    BRCA mutation
    |
    veliparib (ABT-888) • dinaciclib (MK-7965)
    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas (A071401) (NCT02523014)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    09/28/2015
    Primary completion :
    01/01/2026
    Completion :
    01/01/2028
    PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3
    |
    PIK3CA mutation • PTEN mutation
    |
    Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098
    Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. (SkinHealthOnco) (NCT05878964)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    05/22/2023
    Primary completion :
    07/22/2024
    Completion :
    09/22/2024
    CTLA4
    Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer (NCI-2018-01053) (NCT01676753)
    Phase 1b
    Jo Chien
    Completed
    Last update posted :
    09/21/2022
    Initiation :
    12/28/2016
    Primary completion :
    06/30/2020
    Completion :
    02/28/2022
    PGR
    |
    PGR expression
    |
    Keytruda (pembrolizumab) • dinaciclib (MK-7965)
    A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (NCT03850873)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    02/22/2019
    Initiation :
    03/01/2019
    Primary completion :
    09/30/2020
    Completion :
    09/30/2021
    HER-2 • ER
    |
    culmerciclib (TQB3616)
    Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01624441)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/30/2018
    Initiation :
    08/21/2012
    Primary completion :
    09/10/2013
    Completion :
    09/10/2013
    HER-2 • ER • PGR • MCL1
    |
    HER-2 amplification • HER-2 negative
    |
    epirubicin • dinaciclib (MK-7965)
    Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (NCT01188252)
    Phase 1
    Bayer
    Completed
    Last update posted :
    01/09/2017
    Initiation :
    08/01/2010
    Primary completion :
    06/01/2016
    Completion :
    12/01/2016
    CASP3 • CDKN1A • ANXA5
    |
    MCL1 expression
    |
    roniciclib (BAY1000394)
    BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors (NCT02656849)
    Phase 2
    Dana-Farber Cancer Institute
    Withdrawn
    Last update posted :
    07/01/2016
    Initiation :
    02/01/2016
    Primary completion :
    10/01/2019
    Completion :
    05/01/2023
    MYC • CCNE1 • MCL1
    |
    MYC amplification • CCNE1 amplification • MCL1 amplification
    |
    roniciclib (BAY1000394)
    SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) (NCT00732810)
    Phase 2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/05/2015
    Initiation :
    07/01/2008
    Primary completion :
    06/01/2011
    Completion :
    06/01/2011
    HER-2
    |
    HER-2 positive
    |
    erlotinib • capecitabine • dinaciclib (MK-7965)